nach oben

Supportive Care in Cancer

Erschienen in:

22.05.2018 | Commentary

Photobiomodulation therapy in the management of oral mucositis: search for the optimal clinical treatment parameters

verfasst von: Sharon Elad, Praveen Arany, Rene-Jean Bensadoun, Joel B. Epstein, Andrei Barasch, Judith Raber-Durlacher

Erschienen in: Supportive Care in Cancer | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

This commentary attempts to clarify the setting of photobiomodulation (BPM) therapy in the management of oral mucositis. The suggested dose range balances efficacy data with our current understanding about PBM safety. The literature about the molecular basis of photobiomodulation and its controversial relationship to malignant transformation is briefly presented.

Arany PR (2016) Craniofacial wound healing with photobiomodulation therapy: new insights and current challenges. J Dent Res 95:977–984CrossRefPubMed

Zecha JA et al (2016) Low-level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols. Support Care Cancer 24:2793–2805CrossRefPubMedPubMedCentral

Bensadoun RJ, Nair RG (2012) Low-level laser therapy in the prevention and treatment of cancer therapy-induced mucositis: 2012 state of the art based on literature review and meta-analysis. Curr Opin Oncol 24:363–370CrossRefPubMed

Bjordal JM, Bensadoun RJ, Tunèr J, Frigo L, Gjerde K, Lopes-Martins RAB (2011) A systematic review with meta-analysis of the effect of low-level laser therapy (LLLT) in cancer therapy-induced oral mucositis. Support Care Cancer 19:1069–1077CrossRefPubMed

Clarkson JE et al (2010) Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev:CD001973

Migliorati C et al (2013) Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer 21:333–341CrossRefPubMed

Zecha JA et al (2016) Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations. Support Care Cancer 24:2781–2792CrossRefPubMedPubMedCentral

Arany, P.R., et al. Photoactivation of endogenous latent transforming growth factor-beta1 directs dental stem cell differentiation for regeneration. Sci Transl Med 6, 238ra269 (2014)

Karu TI, Pyatibrat LV, Afanasyeva NI (2004) A novel mitochondrial signaling pathway activated by visible-to-near infrared radiation. Photochem Photobiol 80:366–372CrossRefPubMed

10.

Sonis ST, Hashemi S, Epstein JB, Nair RG, Raber-Durlacher JE (2016) Could the biological robustness of low level laser therapy (Photobiomodulation) impact its use in the management of mucositis in head and neck cancer patients. Oral Oncol 54:7–14CrossRefPubMed

11.

Huang YY, Chen AC, Carroll JD, Hamblin MR (2009) Biphasic dose response in low level light therapy. Dose Response 7:358–383CrossRefPubMedPubMedCentral

12.

Jenkins PA, Carroll JD (2011) How to report low-level laser therapy (LLLT)/photomedicine dose and beam parameters in clinical and laboratory studies. Photomed Laser Surg 29:785–787CrossRefPubMed

13.

Tuner J, Jenkins PA (2016) Parameter reproducibility in photobiomodulation. Photomed Laser Surg 34:91–92CrossRefPubMedPubMedCentral

14.

Antunes HS, Herchenhorn D, Small IA, Araújo CMM, Viégas CMP, de Assis Ramos G, Dias FL, Ferreira CG (2017) Long-term survival of a randomized phase III trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy (LLLT) to prevent oral mucositis. Oral Oncol 71:11–15CrossRefPubMed

15.

Khan I, Tang E, Arany P (2015) Molecular pathway of near-infrared laser phototoxicity involves ATF-4 orchestrated ER stress. Sci Rep 5:10581CrossRefPubMedPubMedCentral

Titel: Photobiomodulation therapy in the management of oral mucositis: search for the optimal clinical treatment parameters
verfasst von: Sharon Elad
Praveen Arany
Rene-Jean Bensadoun
Joel B. Epstein
Andrei Barasch
Judith Raber-Durlacher
Publikationsdatum: 22.05.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 10/2018
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4262-6

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Photobiomodulation therapy in the management of oral mucositis: search for the optimal clinical treatment parameters

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2018

Reality of the emetogenic level of irinotecan

Out-of-pocket expenses experienced by rural Western Australians diagnosed with cancer

The perceptions and experiences of osteopathic treatment among cancer patients in palliative care: a qualitative study

Perceptions of masculinity and body image in men with prostate cancer: the role of exercise

Quality versus quantity in end-of-life choices of cancer patients and support persons: a discrete choice experiment

Predictors of outpatients’ request for palliative care service at a medical oncology clinic of a German comprehensive cancer center

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie